Table 1.
Demographics (mean and SD) of participants and clinical assessmentsa
| Descriptive |
p values for pairwise tests |
|||||
|---|---|---|---|---|---|---|
| HC | PD | PSP | HC vs PD | HC vs PSP | PD vs PSP | |
| Age (yr) | 65.5 (5.5) | 67.2 (7.4) | 69.7 (7.7) | 0.66 | 0.164 | 0.52 |
| Education (yr) | 14.8 (3.1) | 14 (2.3) | 12.3 (2.8) | 0.584 | 0.021 | 0.15 |
| Male/female | 13/11 | 18/6 | 8/6 | 0.131 | 0.859 | 0.253 |
| MMSE | 29.75 (0.53) | 29.52 (0.65) | 28.5 (1.74) | 0.649 | <0.001b | 0.009 |
| MoCA | 28.58 (1.44) | 27.88 (1.87) | 24 (3.94) | 0.557 | <0.001b | <0.001b |
| ACER-total | 97.71 (3.25) | 95.25 (3.6) | 87.21 (7.17) | 0.153 | <0.001b | <0.001b |
| Apathy Scale | 10.38 (5.25) | 12.42 (5.55) | 20 (9.49) | 0.528 | <0.001b | 0.003 |
| BIS | 55.71 (9.56) | 58.69 (10.21) | 63.86 (12.44) | 0.591 | 0.063 | 0.316 |
| HADS-Depression | 2.83 (2.84) | 4.25 (2.79) | 7.43 (4.27) | 0.281 | <0.001b | 0.012 |
| HADS-Anxiety | 4.29 (3.53) | 5.17 (3.16) | 6.57 (3.2) | 0.634 | 0.111 | 0.424 |
| RBDSQ | — | 5.38 (3.69) | 3.07 (1.82) | — | — | 0.036 |
| Disease duration (yr) | — | 5.09 (3.05) | 4.24 (2.68) | — | — | 0.397 |
| LEDD | — | 646.6 (509.53) | 323.57 (389.4) | — | — | 0.038 |
| UPDRS-III | — | 28.21 (12.21) | 33.07 (6.96) | — | — | 0.182 |
| PSPRS | — | — | 30.79 (9.11) | — | — | — |
aGroup difference in sex was examined using χ2 test. A one-way ANOVA was used for group difference with post hoc Tukey HSD p values provided for pairwise comparisons. RBDSQ, disease duration and UPDRS-III were compared with independent-samples t test between PD and PSP. MMSE, Mini-Mental State Examination; MoCA, Montreal Cognition Assessment; ACER, Addenbrooke's Cognitive Examination Revised; BIS, Barratt Impulsiveness Scale; HADS, Hamilton Anxiety and Depression Scale; RBDSQ, REM Sleep Behaviors Screening Questionnaire; LEDD, Levodopa equivalent daily dose; UPDRS, Unified Parkinson's Disease Rating Scale; PSPRS, PSP Rating Scale.
bSignificant p values (p < 0.0016, equivalent to p < 0.05 with Bonferroni correction).